Rituximab biosimilar - Samsung

Drug Profile

Rituximab biosimilar - Samsung

Alternative Names: SAIT-101

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Samsung; Samsung BioLogics
  • Developer Archigen Biotech; Samsung
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Follicular lymphoma; Rheumatoid arthritis

Most Recent Events

  • 14 Dec 2017 Quintiles plans a phase III trial for Rheumatoid arthritis in Bosnia-Herzegovina, Bulgaria, Czech Republic, Germany, Hungary, India, Italy, Mexico, Poland, Korea, Russia, Spain and USA (CTRI/2017/06/00875)
  • 18 Oct 2016 Phase-I clinical trials in Rheumatoid arthritis in Spain, Germany (IV) (EudraCT2014-005368-13)
  • 18 Oct 2016 Archigen Biotech initiates the phase I RAMO-1 trial for Rheumatoid arthritis in Czech Republic (IV, Infusion) (EudraCT2014-005368-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top